Indian drugmaker joins race to find COVID-19 vaccine
Indian drugmaker Zydus Cadila has launched a fast track programme to develop a vaccine for the novel coronavirus COVID-19, which has so far claimed more than 1,600 lives worldwide.
The Ahmedabad-based pharmaceutical company on Saturday, February 15, said it would utilise multiple teams in Europe and India to focus on two separate approaches to developing a vaccine.
The first approach would be towards developing a DNA vaccine against COVID-19’s major viral membrane protein, while the second approach is aimed at using reverse genetics to create a recombinant measles virus (rMV) that would induce antibodies against the novel coronavirus.
Zydus Group chairman Pankaj Patel said: “There is an urgent and pressing need to develop a safe and efficacious vaccine that can prevent the spread of this deadly virus. Our researchers are working to bring a speedy solution to this most devastating outbreak in recent times.”
Etna Biotech, Zydus’ European-based research arm, is responsible for developing the measles reverse genetics technology. The company said this approach had previously been successful in developing a vaccine for SARS.
Zydus’ India based Vaccine Technology Centre will focus on developing the DNA vaccine.
The Indian drugmaker is the latest company to join the race to successfully produce a COVID-19 vaccine.
On Friday, February 15, Johnson & Johnson unit Janssen announced that it had expanded an existing partnership with the US Department of Health and Human Services to develop a vaccine for the novel coronavirus.
The two parties had previously collaborated on developing an ebola vaccine.
The viral outbreak has already had a significant impact on IP, with the International Trademark Association and International AntiCounterfeiting Coalition being forced to call off their planned conferences in Singapore in April.
Sister publication WIPR is running a live blog where you can find all the latest news on what COVID-19 means for IP.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk